New Alzheimer’s Research Can Impact Former NFL Players

03.10.14

One of the looming questions surrounding the NFL concussion settlement has been about the diagnosis and compensation for Mild Cognitive Impairment. How are the levels of impairment defined and who determines if a player is eligible for treatment or compensation? To confuse the issue even more, there have been recent developments in the live diagnosis of CTE. Related to this, there have been several recent positive steps in predicting oncoming symptoms of mild cognitive impairment and alzheimer’s. Georgetown University, Johns Hopkins University and University of Pittsburgh have all conducted promising research toward identifying key predictive markers in people with symptoms of cognitive decline. 

In addition to the more dramatic diagnoses of ALS, CTE (post-mortem), and Alzheimer’s, the proposed NFL settlement provides varying levels of medical treatment or compensation for former players diagnosed with Levels 1.0, 1.5, and 2.0 neurocognitive impairment. As indicated in the settlement agreement, the levels are defined by the National Alzheimer’s Coordinating Center’s Clinical Dementia Rating (CDR) scale and determined in accordance with a battery of neuropsychological tests detailed in an exhibit in the settlement papers. The tests include the Wechsler Adult Intelligence Scale (WAIS), the Advanced Clinical Solutions (ACS) Suboptimal Effort and the Test of Premorbid Functioning (TOPF).

Researchers at Georgetown University claim that a blood test can predict with 90 percent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease within three years.

 

Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder. 

 

According to the study’s author, neurologist Dr. Howard J. Federoff, “the preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention, and biomarkers defining this asymptomatic period are critical for successful development and application of these therapeutics.”

Essentially, the study took blood tests each year for five years of 525 people over age 70 who had previously shown no symptoms of cognitive decline. In the ensuing 5 years, of the participants who developed symptoms of Alzheimer’s or Mild Cognitive Impairment, 90% of them could have been predicted by the presence of 10 particular lipids in the blood. (It would helpful to know how many of the 525 people did actually develop symptoms. Is the 90% figure 9 out of 10, or 45 out of 50, or 90 out of 100?) Still, 90% is a remarkable predictive figure.

Research performed at Johns Hopkins University showed that in a 10 year study involving 265 participants, by analyzing spinal fluid, researchers could predict mild cognitive decline five years before noticeable changes in memory occurred. In this time, two proteins, phosphorylated tau and beta amyloid in the spinal fluid, changed significantly. The ratio between tau and amyloid predicted the development of Alzheimer’s symptoms and memory loss.

Meanwhile, at the University of Pittsburgh, researchers studied a group of 91 seniors with no signs of dementia for a link to hardening of the arteries. The study shows that adults with hardening of the arteries are more likely to have beta-amyloid plaques in their brain even if they have no signs of dementia. Although researchers still do not know whether amyloid plaques in the brain are the cause or a byproduct of dementia, their presence is associated with and considered the hallmark of Alzheimer’s disease. According to study author Timothy M. Hughes, Ph.D.:

This research shows more evidence that vascular health and brain health are closely connected.

 

Although there are no known “cures” for Alzheimer’s or dementia, it still may be helpful to confidently predict a problem, the sooner the better. For former NFL players, accurate predictive tests like these may help them deal with difficult uncertainty and with planning legal, financial and personal issues.